Product Description
Mechanisms of Action: DNA Damager
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous,Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: India
Approved Indications: None
Known Adverse Events: None
Company: Wockhardt
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Skin Diseases, Bacterial|Communicable Diseases
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| W-771/2349-301 | P3 |
Completed |
Communicable Diseases|Skin Diseases, Bacterial |
2018-09-25 |
75% |
| W 771/2349-101 | P1 |
Completed |
Healthy Volunteers |
2013-06-01 |
|
| WCK771/P-I/MD/08 | P1 |
Completed |
Healthy Volunteers |
2012-02-07 |
28% |